echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > 3 months to introduce 5 innovative products! Thought Di medicine in the research pipeline is accelerating expansion

    3 months to introduce 5 innovative products! Thought Di medicine in the research pipeline is accelerating expansion

    • Last Update: 2021-01-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 8th, Spirit Pharmaceuticals announced a partnership with SELLAS Life Sciences Group to obtain exclusive development and commercial rights to all adaptations of the latter's two cancer immunotherapy innovations in Greater China.
    this is another important step in expanding the product pipeline, following the introduction of two new analgesics in October and a new cancer drug from Aravive in November.
    two new drugs introduced by Linpepimut-S (GPS) and the seven-priced new generation of Galinpepimut-S plus (GPS plus).
    , GPS is an innovative new cancer immunotherapy drug targeting WT1 (Wilms Tumor Protein) for the treatment of WT1 antigen over-expression of malignant hematomas and solid tumors.
    It consists of 4 peptide chains, up to 25 antigens, suitable for the vast majority of human lewd cell tissue compatible antigen (HLA) types worldwide, can stimulate their own immune system strong immune response to WT1 antigens, monotherapy or combination therapy can effectively kill tumor cells in the body and strengthen the immune surveillance of tumor cells, is expected to become the target of the first innovative drug (first-in-class).
    another GPS plus for the seven-price version of GPS, adding three peptide segments to the GPS in order to achieve better treatment results and fuller HLA coverage. according to
    , GPS and GPS plus are mature freeze-dried preparations, using off-the-skin injection administration, which can be used as a single drug for maintenance therapy in low-risk clinical situations, but also with PD-1/PD-L1 antibodies and other therapeutic drugs combined to improve efficacy.
    clinical trial results show that GPS has a high immunogenicity, can delay the recurrence of disease, and adverse events are mainly weak local reactions at the injection site.
    currently, a Phase 3 clinical trial of GPS monodring for acute myeloid leukemia (AML) is under way, and a Phase 1/2 clinical trial of a drug in union with PD-1/PD-L1 antibodies is under way.
    , it also received fast-track or orphan drug qualifications from the FDA and the European EMA for adaptations such as multiple myeloma (MM), AML, and malignant thoracic mesothelioma (MPM), respectively.
    gps plus is about to enter the clinical development phase.
    it is worth mentioning that in a partnership with Aravive in November, Wedi Pharmaceuticals intends to obtain exclusive authorization for clinical development and commercialization of the new cancer drug AVB-500 in the field of cancer in Greater China for over $210 million.
    AVB-500 is a specific high affinity Fc fusion protein specific to GAS6, and is also a new GAS6-AXL signal pathens inhibitor, which is about to enter Phase 3 registered clinical studies.
    Two innovative analgesics, RMX1001 and RMX1002, introduced from Haihe pharmaceuticals in October, have the potential to replace traditional nonsteroidal anti-inflammatory drugs as new analgesics, according to an earlier press release, after completing Phase 1 clinical studies in China.
    , the RMX1001 is a next-generation Cox-2 inhibitor and the RMX1002 is an EP4 subject antagonist.
    References: sic. Retrieved Nov 11, 2020, Fromdy Pharmaceuticals announced that it has won exclusive rights to develop, produce and commercialize two new analgesics in China in partnership with Haihe Pharmaceuticals. Retrieved Oct 27, 2020, from Source: Medical Mission Hills
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.